{"product_id":"astellas-bcg-matrix","title":"Astellas Pharma Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAstellas Pharma’s BCG Matrix preview highlights how its flagship oncology and urology franchises may occupy different quadrants—some products acting as Stars with high growth potential while older generics risk becoming Cash Cows or Dogs as competition intensifies; emerging pipeline assets could be Question Marks needing strategic investment. This snapshot signals where management should allocate R\u0026amp;D and commercial capital to maximize returns. Purchase the full BCG Matrix to get quadrant-level placements, data-driven recommendations, and downloadable Word and Excel files to guide investment and portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePADCEV (Enfortumab Vedotin)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, PADCEV (enfortumab vedotin) is a high-growth Star after expanded first-line approval for advanced bladder cancer, achieving ~18% global urothelial market share and generating ~$1.6B in 2025 revenue for Astellas.\u003c\/p\u003e\n\u003cp\u003eIts pembrolizumab combo boosted uptake, driving a 36% year-over-year US volume rise in 2025 and lifting Astellas oncology sales growth by ~22%.\u003c\/p\u003e\n\u003cp\u003eAstellas is funding Phase III and neoadjuvant trials aimed at muscle-invasive disease, budgeting \u0026gt;$400M through 2026 to secure earlier-line indications and sustain growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVEZEREVO (Fezolinetant)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVEZEREVO (fezolinetant), a first-in-class non-hormonal NK3 receptor antagonist for menopause vasomotor symptoms, is a Star: 2024-2025 launches drove rapid uptake in North America and Europe with estimated 2025 prescriptions \u0026gt;220,000 and peak-market share projections ~18% in treated population.\u003c\/p\u003e\n\u003cp\u003eHigh marketing spend is needed—Astellas guided 2025 promotional investment ~USD 240–270M—but fezolinetant’s novel MOA and a women’s health market growing ~6–8% CAGR position it as a key mid-term revenue driver toward 2026–2028 targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIZERVAY (Avacincaptad Pegol)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcquired via the Iveric Bio merger (completed Jan 2023), IZERVAY (avacincaptad pegol) is Astellas’ high-growth Stars asset targeting geographic atrophy (GA) from age-related macular degeneration, a market with incidence ~1.5M US+EU patients and projected \u0026gt;$4B annual peak demand by 2030.\u003c\/p\u003e\n\u003cp\u003eCompeting in a newly opened, high-demand space with few approved options, IZERVAY needs substantial global launch spend—estimated $200–400M capex\/marketing through 2025—to secure payor access and drive uptake.\u003c\/p\u003e\n\u003cp\u003eAs penetration rises (DCR 2024 launch uptake climbing to ~10–15% in treated GA cohorts) IZERVAY is positioned to be a dominant ophthalmology leader, targeting top-line peak sales of $1.5–2.5B by 2028 per internal forecasts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXOSPATA (Gilteritinib)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXOSPATA (gilteritinib) remains a Star for Astellas with ~40% global market share in FLT3-mutant acute myeloid leukemia and FY2024 sales of ~$950M, driven by precision-diagnosis uptake and ~8–10% annual oncology market growth in targeted therapies.\u003c\/p\u003e\n\u003cp\u003eOngoing pediatric label expansion and combination trials (notably azacitidine and venetoclax studies) plus expected launch in additional markets keep it a top revenue driver despite new entrants and pressure on pricing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~40% market share; FY2024 sales ~$950M\u003c\/li\u003e\n\u003cli\u003eTargeted oncology growth ~8–10% CAGR\u003c\/li\u003e\n\u003cli\u003ePediatric and combo trials ongoing\u003c\/li\u003e\n\u003cli\u003eHigh diagnostic adoption boosting patient identification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell Therapy Pipeline (Focus Area)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAstellas has named cell therapy a high-priority investment, targeting market-leading innovation in regenerative medicine and classifying it as a future star in its BCG matrix; several programs are in late-stage trials or early commercialization as of 2025 with total R\u0026amp;D spend for cell\/gene modalities of ~¥65–80 billion (2024–25 plan).\u003c\/p\u003e\n\u003cp\u003eSpecialized manufacturing capex is large—Astellas committed ~¥30 billion in 2023–25 to cell therapy facilities and partnerships, reflecting scaling for high-growth demand and higher margin potential once commercialized.\u003c\/p\u003e\n\u003cp\u003eClinical readouts and early revenues from partnered CAR-T and allogeneic candidates position the platform in a high-growth niche, but commercialization timelines and reimbursement remain execution risks into 2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh priority: designated future star\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend: ~¥65–80 billion (2024–25)\u003c\/li\u003e\n\u003cli\u003eCapex: ~¥30 billion (2023–25)\u003c\/li\u003e\n\u003cli\u003eStatus: late-stage\/early commercial; CAR-T, allogeneic candidates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAstellas’ Stars: PADCEV, XOSPATA, VEZEREVO, IZERVAY \u0026amp; Cell Therapy Drive ~$4.35B by 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePADCEV, VEZEREVO, IZERVAY, XOSPATA and cell therapy are Stars for Astellas—high-growth, high-share assets driving 2025–28 revenue; combined 2025 sales ~$4.35B (PADCEV $1.6B, XOSPATA $0.95B, IZERVAY ~$0.35B, VEZEREVO ~$0.4B, cell therapy early rev ~USD 50M) with R\u0026amp;D\/capex commitments ~$1.0B (2023–26).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 sales\u003c\/th\u003e\n\u003cth\u003eMarket share\/notes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePADCEV\u003c\/td\u003e\n\u003ctd\u003e$1.6B\u003c\/td\u003e\n\u003ctd\u003e~18% urothelial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXOSPATA\u003c\/td\u003e\n\u003ctd\u003e$0.95B\u003c\/td\u003e\n\u003ctd\u003e~40% FLT3-AML\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVEZEREVO\u003c\/td\u003e\n\u003ctd\u003e$0.4B\u003c\/td\u003e\n\u003ctd\u003e~18% peak treated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIZERVAY\u003c\/td\u003e\n\u003ctd\u003e$0.35B\u003c\/td\u003e\n\u003ctd\u003e10–15% initial GA uptake\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell therapy\u003c\/td\u003e\n\u003ctd\u003e$0.05B\u003c\/td\u003e\n\u003ctd\u003elate-stage\/early commercial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored BCG Matrix analysis of Astellas’ portfolio: Stars, Cash Cows, Question Marks, Dogs with invest\/hold\/divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix placing Astellas units in quadrants for quick portfolio decisions and exec-ready printing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXTANDI (Enzalutamide)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXTANDI (enzalutamide) remains Astellas Pharma’s oncology cash cow, with global annual sales of about $4.9 billion in fiscal 2024 and dominant market share in metastatic castration-resistant prostate cancer.\u003c\/p\u003e\n\u003cp\u003eThe market is mature and patent expiries loom in some regions, yet XTANDI’s high margins and ~30% operating cash conversion help fund Astellas’ R\u0026amp;D spend of ~$2.2 billion in 2024.\u003c\/p\u003e\n\u003cp\u003eMinimal incremental promotion is needed as XTANDI is entrenched as standard of care worldwide, so its free cash flow continues to support pipeline programs and M\u0026amp;A optionality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePROGRAF (Tacrolimus)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePROGRAF (tacrolimus) remains a cash cow for Astellas Pharma, generating steady revenue—estimated at ~JPY 120–140 billion annually in 2024 across global markets—with gross margins above 60% due to manufacturing scale and pricing in transplant niches.\u003c\/p\u003e\n\u003cp\u003eGeneric tacrolimus pressures volumes, but brand loyalty and extended‑release Advagraf\/osmotic formulations held ~35% global market share in 2024, keeping ASPs higher than commoditized generics.\u003c\/p\u003e\n\u003cp\u003ePROGRAF provides predictable cash flow used to service Astellas’ net debt (¥~1.0–1.2 trillion at FY2024) and support dividends, contributing materially to free cash flow stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBETANIS \/ MYRBETRIQ (Mirabegron)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBETANIS\/MYRBETRIQ (mirabegron) is a market leader in overactive bladder within urology, holding roughly 35% global share in 2024 and a long-established safety profile from \u0026gt;1.5 million patient-years of exposure.\u003c\/p\u003e\n\u003cp\u003eWith urology market CAGR stabilized near 2% (2022–24), Astellas has shifted to a harvest strategy—cutting aggressive promotion and boosting operating margins; MYRBETRIQ net sales reached ¥180 billion (≈$1.3B) in FY2024.\u003c\/p\u003e\n\u003cp\u003eCash flow from this franchise is being redeployed into higher-growth areas: Astellas increased R\u0026amp;D allocations for gene therapy and ophthalmology by ~15% in 2024, funding clinical programs and M\u0026amp;A targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXTANDI (Japan and Established Markets)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eXTANDI (enzalutamide) in Japan and other established markets is a steady cash cow: global 2024 sales were about $4.5B and Japan accounted for roughly $700M, supported by deep market penetration and broad reimbursement since 2014.\u003c\/p\u003e\n\u003cp\u003eLow market growth is offset by recurring prescriptions—annual patient persistence ~70% at 12 months—and efficient distribution, keeping XTANDI key to Astellas’ FY2024 operating cash flow and margin stability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 sales ~$4.5B global; Japan ~$700M\u003c\/li\u003e\n\u003cli\u003e12‑month persistence ~70%\u003c\/li\u003e\n\u003cli\u003eEstablished reimbursement since 2014\u003c\/li\u003e\n\u003cli\u003eSupports Astellas’ FY2024 cash flow and margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCRESEMBA (Isavuconazole)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCRESEMBA (isavuconazole) is a cash cow for Astellas, holding ~30–35% share of the hospital antifungal market for invasive aspergillosis and mucormycosis in 2024–2025 and generating high gross margins (~70%) from low ongoing R\u0026amp;D and sales investment.\u003c\/p\u003e\n\u003cp\u003eIt needs minimal maintenance spend, delivers steady annual net product revenue estimated at ~$450–500M in 2024, and funds Astellas’ 2025 strategic priorities in oncology and gene therapy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrong hospital share: 30–35% (2024)\u003c\/li\u003e\n\u003cli\u003eNet revenue: ~$450–500M (2024)\u003c\/li\u003e\n\u003cli\u003eGross margin: ~70%\u003c\/li\u003e\n\u003cli\u003eLow maintenance CAPEX\/R\u0026amp;D; high free cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAstellas’ 4 cash cows fuel ¥650–750B revenue, high margins and major R\u0026amp;D\/M\u0026amp;A war chest\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXTANDI, PROGRAF, MYRBETRIQ, and CRESEMBA are Astellas cash cows in 2024–25, jointly generating ~¥650–750 billion (~$4.8–5.5B) annually, high gross margins (60–70%), and steady free cash flow used for R\u0026amp;D (~¥300B in 2024), debt service (¥1.0–1.2T) and M\u0026amp;A.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eXTANDI\u003c\/td\u003e\n\u003ctd\u003e$4.5–4.9B\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003ctd\u003eLeader\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePROGRAF\u003c\/td\u003e\n\u003ctd\u003e¥120–140B\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003ctd\u003eStrong\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMYRBETRIQ\u003c\/td\u003e\n\u003ctd\u003e¥180B\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRESEMBA\u003c\/td\u003e\n\u003ctd\u003e$450–500M\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003ctd\u003e30–35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eAstellas Pharma BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact Astellas Pharma BCG Matrix report you'll receive after purchase—no watermarks or demo content, just a fully formatted, analysis-ready document tailored for strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748431606137,"sku":"astellas-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/astellas-bcg-matrix.png?v=1772208030","url":"https:\/\/growthsharematrix.com\/products\/astellas-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}